These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 18849536)

  • 1. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics in Europe: barriers and opportunities.
    Gurwitz D; Zika E; Hopkins MM; Gaisser S; Ibarreta D
    Public Health Genomics; 2009; 12(3):134-41. PubMed ID: 19204415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial drug development--the past, the present, and the future.
    Powers JH
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():23-31. PubMed ID: 15522037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Traditional and translational medicine].
    Godfraind T
    Bull Acad Natl Med; 2007; 191(4-5):715-25; discussion 725-6. PubMed ID: 18225425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    Ross JS; Ginsburg GS
    Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics at 50: genomic personalization comes of age.
    Urban TJ; Goldstein DB
    Sci Transl Med; 2014 Jan; 6(220):220ps1. PubMed ID: 24452261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics: historical perspective and current status.
    Kalow W
    Methods Mol Biol; 2005; 311():3-15. PubMed ID: 16100395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.